Akebia Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Akebia Therapeutics, Inc. had total assets of $377m, total liabilities of $344m and shareholders' equity of $32.6m. It held $185m in cash against $52.4m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Akebia Therapeutics, Inc.: balance sheet, annual
Fiscal year	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	33	50	187	70	105	147	229	150	90	43	52	185	156
Receivables	0	—	34	34	17	39	27	52	40	39	34	47	54
Inventory	—	—	—	—	114	116	61	37	22	16	16	16	13
Total current assets	110	141	296	358	468	310	371	271	185	118	114	253	230
Goodwill	—	—	—	—	55	55	55	59	59	59	59	59	59
Total assets	111	143	300	364	997	771	644	529	356	242	221	377	350
Accounts payable	2	2	2	7	43	39	41	34	18	15	15	21	9
Deferred revenue (current)	—	—	82	82	57	40	15	21	4	0	0	3	6
Total current liabilities	7	12	114	141	266	208	187	261	130	100	81	163	161
Short-term debt	—	—	—	—	15	—	0	98	32	18	0	0	25
Long-term debt	—	—	—	—	—	76	96	0	34	17	39	48	25
Total debt	0	0	0	0	30	80	100	100	67	35	43	52	52
Total liabilities	7	12	232	242	361	376	397	455	351	272	270	344	325
Shareholders' equity	104	131	68	123	636	393	244	74	5	−31	−49	33	25
Shares outstanding	—	—	77m	95m	117m	122m	148m	177m	184m	195m	225m	265m	272m

US$ millions unless shown otherwise. Fiscal quarters.

Akebia Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	32	34	62	73	66	47	63	54
Inventory	20	16	20	17	19	16	13	13
Total current assets	100	114	204	235	258	253	243	230
Goodwill	59	59	59	59	59	59	59	59
Total assets	207	221	310	346	364	377	363	350
Accounts payable	13	15	13	12	10	21	8	9
Deferred revenue (current)	—	0	1	6	4	3	4	6
Total current liabilities	66	81	91	119	133	163	174	161
Short-term debt	0	0	—	—	—	0	12	25
Long-term debt	38	39	47	47	48	48	36	25
Total debt	38	39	47	47	48	48	49	50
Total liabilities	258	270	286	316	323	344	335	325
Shareholders' equity	−50	−49	25	29	42	33	27	25
Shares outstanding	212m	225m	262m	263m	265m	265m	268m	272m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AKBA vs PBYI AKBA vs IDYA AKBA vs ANAB AKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Akebia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akebia Therapeutics, Inc.